Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 30405135.
- Also identified by DOI 10.1038/s41467-018-07131-y and PMC identifier 6220188.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
PD-L1 immunohistochemistry correlates only moderately with patient survival and response to PD-(L)1 treatment. Heterogeneity of tumor PD-L1 expression might limit the predictive value of small biopsies. Here we show that tumor PD-L1 and PD-1 expression can be quantified non-invasively using PET-CT in patients with non-small-cell lung cancer. Whole body PD-(L)1 PET-CT reveals significant tumor tracer uptake heterogeneity both between patients, as well as within patients between different tumor lesions.
Medical subject headings
- B7-H1 Antigen
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Positron-Emission Tomography
- Programmed Cell Death 1 Receptor
- Whole Body Imaging